Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products-Content and Format; Draft Guidance for Industry; Availability, 72104-72105 [2014-28242]

Download as PDF 72104 Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2014–D–1551] Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products—Content and Format; Draft Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ‘‘Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products—Content and Format.’’ This draft guidance is intended to assist applicants in complying with the new content and format requirements in the Pregnancy, Lactation, and Females and Males of Reproductive Potential subsections of labeling for human prescription drug and biological products, as described in the final rule, Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling. The rule, which is being published concurrently with this draft guidance, is referred to as the ‘‘Pregnancy and Lactation Labeling Rule’’ (PLLR). The draft guidance will assist applicants in developing labeling for new products, revising existing labeling, and implementing the content and format requirements of the PLLR for human prescription drug and biological products. SUMMARY: Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by February 2, 2015. DATES: Submit written requests for single copies of this draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor, Silver Spring, MD 20993, or Office of Communication, Outreach and Development, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. G102, mstockstill on DSK4VPTVN1PROD with NOTICES2 ADDRESSES: VerDate Sep<11>2014 18:30 Dec 03, 2014 Jkt 235001 Silver Spring, MD 20993. Send one selfaddressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. Submit electronic comments on the draft guidance to http:// www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Division of Pediatric and Maternal Health, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6312, Silver Spring, MD 20993–0002, 301–796–2200; or Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993, 240–402– 7911. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a draft guidance for industry entitled ‘‘Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products—Content and Format.’’ The draft guidance provides recommendations on how to develop and revise professional labeling that meets the new content and format requirements of the Pregnancy, Lactation, and Females and Males of Reproductive Potential subsections of labeling for human prescription drug and biological products. Specifically, it provides information to assist applicants in preparing subsections 8.1 Pregnancy, 8.2 Lactation, and 8.3 Females and Males of Reproductive Potential of the USE IN SPECIFIC POPULATIONS section of the full prescribing information under 21 CFR 201.56(d)(1) and 201.57(c)(9)(i) through (iii), as described in the PLLR. The PLLR provides a framework to clearly communicate information on the benefits and risks of drug use during pregnancy and lactation to help facilitate prescribing decisions. The PLLR also includes a subsection on females and males of reproductive potential to address issues in these populations that are linked to pregnancy either directly or indirectly. The draft guidance provides recommendations to applicants submitting new drug applications (NDAs), efficacy supplements to approved NDAs, biologics license applications (BLAs) PO 00000 Frm 00001 Fmt 4701 Sfmt 4703 (for biological products that are regulated as drugs), and efficacy supplements to BLAs, as well as to applicants that have previously submitted such applications during the time periods specified in the implementation plan set out in the preamble to the PLLR. FDA may revise other Agency guidances as needed and appropriate to reflect the PLLR content and format requirements and the recommendations in this guidance, once it has been finalized. This draft guidance is one of a series of guidances FDA is developing, or has developed, to assist applicants with the content and format of the labeling for human prescription drug and biological products. In the Federal Register of January 24, 2006 (71 FR 3999), FDA announced the availability of final guidances on the content and format of the ‘‘Adverse Reactions’’ (http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm075057.pdf) and ‘‘Clinical Studies’’ (http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ucm075059.pdf) sections of labeling. In the Federal Register of October 19, 2009 (74 FR 53507), FDA announced the availability of final guidance on determining established pharmacologic class for use in the ‘‘Highlights of Prescribing Information’’ (http://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ UCM186607.pdf). In the Federal Register of March 23, 2010 (75 FR 13766), FDA announced the availability of final guidance on the content and format of the ‘‘Dosage and Administration’’ section of labeling (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/UCM075066. pdf). In the Federal Register of October 12, 2011 (76 FR 63303), FDA announced the availability of final guidance on the content and format of the ‘‘Warnings and Precautions,’’ ‘‘Contraindications,’’ and ‘‘Boxed Warning’’ sections of labeling (http://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ UCM075096.pdf),and in the Federal Register of March 3, 2009 (74 FR 9250), FDA announced the availability of draft guidance on the content and format of the ‘‘Clinical Pharmacology’’ section of labeling (http://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ UCM109739.pdf). In the Federal Register of February 25, 2013 (78 FR 12760), FDA announced the availability E:\FR\FM\04DEN2.SGM 04DEN2 Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Notices mstockstill on DSK4VPTVN1PROD with NOTICES2 of final guidance implementing the ‘‘Physician Labeling Rule’’ (January 24, 2006, 71 FR 3922) content and format requirements of labeling for human prescription drug and biological products under §§ 201.56(d) and 201.57 (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ ucm075082.pdf). In the Federal Register of February 28, 2013 (78 FR 13686), FDA announced the availability of draft guidance on the placement and content of pediatric information in the labeling for human prescription drug and biological products in accordance with the Physician Labeling Rule (http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/UCM341394. pdf). The labeling requirements and these guidances are intended to make information in prescription drug labeling easier for health care practitioners to access, read, and use. This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the Agency’s current thinking on implementing the PLLR content and format requirements for labeling for human prescription drug and biological products. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. VerDate Sep<11>2014 18:30 Dec 03, 2014 Jkt 235001 An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. II. Comments Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http:// www.regulations.gov. III. Paperwork Reduction Act of 1995 This guidance refers to previously approved collections of information that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collection of information in 21 CFR 201.56 and 201.57 has been approved under OMB control number 0910–0572. The collection of information in 21 CFR 314.70 and 314.97 for submitting supplements to an approved application, the collection of information in 21 CFR 314.50(e) for submitting labeling for an application, PO 00000 Frm 00002 Fmt 4701 Sfmt 9990 72105 and the collection of information in 21 CFR 314.90 for submitting waiver requests for an application have been approved under OMB control number 0910–0001. The collection of information in 21 CFR 601.12 for submitting supplements to an approved application has been approved under OMB control number 0910–0338. In addition, the information collection provisions of the PLLR have been submitted to OMB for review, as required by section 3507(d) of the Paperwork Reduction Act. Prior to the effective date of the PLLR, FDA will publish a notice in the Federal Register announcing OMB’s decision to approve, modify, or disapprove the information collection provisions in the final rule. IV. Electronic Access Persons with access to the Internet may obtain the draft guidance at either http://www.fda.gov/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/default.htm, http:// www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatory Information/default.htm, or http:// www.regulations.gov. Dated: November 25, 2014. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2014–28242 Filed 12–3–14; 8:45 am] BILLING CODE 4164–01–P E:\FR\FM\04DEN2.SGM 04DEN2

Agencies

[Federal Register Volume 79, Number 233 (Thursday, December 4, 2014)]
[Notices]
[Pages 72104-72105]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-28242]



Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / 
Notices

[[Page 72104]]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-D-1551]


Pregnancy, Lactation, and Reproductive Potential: Labeling for 
Human Prescription Drug and Biological Products--Content and Format; 
Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
availability of a draft guidance for industry entitled ``Pregnancy, 
Lactation, and Reproductive Potential: Labeling for Human Prescription 
Drug and Biological Products--Content and Format.'' This draft guidance 
is intended to assist applicants in complying with the new content and 
format requirements in the Pregnancy, Lactation, and Females and Males 
of Reproductive Potential subsections of labeling for human 
prescription drug and biological products, as described in the final 
rule, Content and Format of Labeling for Human Prescription Drug and 
Biological Products; Requirements for Pregnancy and Lactation Labeling. 
The rule, which is being published concurrently with this draft 
guidance, is referred to as the ``Pregnancy and Lactation Labeling 
Rule'' (PLLR). The draft guidance will assist applicants in developing 
labeling for new products, revising existing labeling, and implementing 
the content and format requirements of the PLLR for human prescription 
drug and biological products.

DATES: Although you can comment on any guidance at any time (see 21 CFR 
10.115(g)(5)), to ensure that the Agency considers your comment on this 
draft guidance before it begins work on the final version of the 
guidance, submit either electronic or written comments on the draft 
guidance by February 2, 2015.

ADDRESSES: Submit written requests for single copies of this draft 
guidance to the Division of Drug Information, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10001 New 
Hampshire Ave., Hillandale Bldg., 4th Floor, Silver Spring, MD 20993, 
or Office of Communication, Outreach and Development, Center for 
Biologics Evaluation and Research (CBER), Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 71, Rm. G102, Silver Spring, MD 20993. 
Send one self-addressed adhesive label to assist that office in 
processing your requests. See the SUPPLEMENTARY INFORMATION section for 
electronic access to the guidance document.
    Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets 
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Division of Pediatric and Maternal 
Health, Center for Drug Evaluation and Research, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6312, Silver 
Spring, MD 20993-0002, 301-796-2200; or Stephen Ripley, Center for 
Biologics Evaluation and Research, Food and Drug Administration, 10903 
New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993, 240-
402-7911.

SUPPLEMENTARY INFORMATION: 

I. Background

    FDA is announcing the availability of a draft guidance for industry 
entitled ``Pregnancy, Lactation, and Reproductive Potential: Labeling 
for Human Prescription Drug and Biological Products--Content and 
Format.'' The draft guidance provides recommendations on how to develop 
and revise professional labeling that meets the new content and format 
requirements of the Pregnancy, Lactation, and Females and Males of 
Reproductive Potential subsections of labeling for human prescription 
drug and biological products. Specifically, it provides information to 
assist applicants in preparing subsections 8.1 Pregnancy, 8.2 
Lactation, and 8.3 Females and Males of Reproductive Potential of the 
USE IN SPECIFIC POPULATIONS section of the full prescribing information 
under 21 CFR 201.56(d)(1) and 201.57(c)(9)(i) through (iii), as 
described in the PLLR.
    The PLLR provides a framework to clearly communicate information on 
the benefits and risks of drug use during pregnancy and lactation to 
help facilitate prescribing decisions. The PLLR also includes a 
subsection on females and males of reproductive potential to address 
issues in these populations that are linked to pregnancy either 
directly or indirectly. The draft guidance provides recommendations to 
applicants submitting new drug applications (NDAs), efficacy 
supplements to approved NDAs, biologics license applications (BLAs) 
(for biological products that are regulated as drugs), and efficacy 
supplements to BLAs, as well as to applicants that have previously 
submitted such applications during the time periods specified in the 
implementation plan set out in the preamble to the PLLR. FDA may revise 
other Agency guidances as needed and appropriate to reflect the PLLR 
content and format requirements and the recommendations in this 
guidance, once it has been finalized.
    This draft guidance is one of a series of guidances FDA is 
developing, or has developed, to assist applicants with the content and 
format of the labeling for human prescription drug and biological 
products. In the Federal Register of January 24, 2006 (71 FR 3999), FDA 
announced the availability of final guidances on the content and format 
of the ``Adverse Reactions'' (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm075057.pdf) and 
``Clinical Studies'' (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075059.pdf) 
sections of labeling. In the Federal Register of October 19, 2009 (74 
FR 53507), FDA announced the availability of final guidance on 
determining established pharmacologic class for use in the ``Highlights 
of Prescribing Information'' (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM186607.pdf). In 
the Federal Register of March 23, 2010 (75 FR 13766), FDA announced the 
availability of final guidance on the content and format of the 
``Dosage and Administration'' section of labeling (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM075066.pdf). In the Federal Register of October 12, 2011 (76 FR 
63303), FDA announced the availability of final guidance on the content 
and format of the ``Warnings and Precautions,'' ``Contraindications,'' 
and ``Boxed Warning'' sections of labeling (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM075096.pdf),and in the Federal Register of March 3, 2009 (74 FR 
9250), FDA announced the availability of draft guidance on the content 
and format of the ``Clinical Pharmacology'' section of labeling (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM109739.pdf). In the Federal Register of February 25, 2013 
(78 FR 12760), FDA announced the availability

[[Page 72105]]

of final guidance implementing the ``Physician Labeling Rule'' (January 
24, 2006, 71 FR 3922) content and format requirements of labeling for 
human prescription drug and biological products under Sec. Sec.  
201.56(d) and 201.57 (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075082.pdf). In 
the Federal Register of February 28, 2013 (78 FR 13686), FDA announced 
the availability of draft guidance on the placement and content of 
pediatric information in the labeling for human prescription drug and 
biological products in accordance with the Physician Labeling Rule 
(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM341394.pdf).
    The labeling requirements and these guidances are intended to make 
information in prescription drug labeling easier for health care 
practitioners to access, read, and use.
    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized, will represent the Agency's current thinking on implementing 
the PLLR content and format requirements for labeling for human 
prescription drug and biological products. It does not create or confer 
any rights for or on any person and does not operate to bind FDA or the 
public. An alternative approach may be used if such approach satisfies 
the requirements of the applicable statutes and regulations.

II. Comments

    Interested persons may submit either electronic comments regarding 
this document to http://www.regulations.gov or written comments to the 
Division of Dockets Management (see ADDRESSES). It is only necessary to 
send one set of comments. Identify comments with the docket number 
found in brackets in the heading of this document. Received comments 
may be seen in the Division of Dockets Management between 9 a.m. and 4 
p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

III. Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of 
information that are subject to review by the Office of Management and 
Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-
3520). The collection of information in 21 CFR 201.56 and 201.57 has 
been approved under OMB control number 0910-0572. The collection of 
information in 21 CFR 314.70 and 314.97 for submitting supplements to 
an approved application, the collection of information in 21 CFR 
314.50(e) for submitting labeling for an application, and the 
collection of information in 21 CFR 314.90 for submitting waiver 
requests for an application have been approved under OMB control number 
0910-0001. The collection of information in 21 CFR 601.12 for 
submitting supplements to an approved application has been approved 
under OMB control number 0910-0338. In addition, the information 
collection provisions of the PLLR have been submitted to OMB for 
review, as required by section 3507(d) of the Paperwork Reduction Act. 
Prior to the effective date of the PLLR, FDA will publish a notice in 
the Federal Register announcing OMB's decision to approve, modify, or 
disapprove the information collection provisions in the final rule.

IV. Electronic Access

    Persons with access to the Internet may obtain the draft guidance 
at either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm, or http://www.regulations.gov.

    Dated: November 25, 2014.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2014-28242 Filed 12-3-14; 8:45 am]
BILLING CODE 4164-01-P